The leading drug developers
already work with Tempus.

Hundreds of biopharma teams. A decade of refined real-world multimodal data. Every engagement improving a decision in drug development.

95%
of the top 20 pharma companies
200+
biopharma companies
$1B+
in signed data contracts
5x
documented customer ROI on Tempus data
Featured collaborations · publicly announced
AstraZeneca Pfizer GSK Merck BioNTech Gilead Bristol Myers Squibb Recursion
Each name links to the public press release announcing the partnership.
Active engagements

Selected blinded engagements.

Anonymized examples from current customer work across oncology and rare disease. Each represents a drug-development decision informed by Tempus data.

A biopharma company
Blinded
Target validation · Trial design
Validating a novel target and informing trial design for a first-in-class therapeutic
Tempus's de-identified multimodal data supported validation of a novel target and informed trial design for a first-in-class therapeutic.
Read the case study →
A biotech company
Blinded
NSCLC · External control arm
Real-world external controls for regulatory decision-making
A biotech needed to contextualize its Phase 1b/2a trial for mNSCLC patients with a specific mutation. Tempus constructed a real-world external control arm as a benchmark for the regulatory submission.
Read the case study →
A biopharma company
Blinded
Indication expansion
Guiding indication expansion with multimodal real-world data
Analysis of biomarker prevalence across Tempus's multimodal real-world data helped identify new opportunities, prioritize R&D, and inform future trial design.
Read the case study →
A biopharma company
Blinded
NSCLC · Development strategy
Reduce time to launch with Tempus and multimodal data
A biopharma simplified its development approach to TROPION-Lung01, driving down time to launch and saving the cost of an unnecessary Phase III study.
Read the case study →
A biopharma company
Blinded
Franchise expansion
Informing a franchise expansion strategy for an approved targeted therapy
Tempus's multimodal real-world data analysis identified the highest-opportunity adjacent indications, helping prioritize R&D for the next wave of the franchise.
Read the case study →
A biotech company
Blinded
Bladder · Biomarker discovery
Biomarker-driven strategy for a first-in-class inhibitor in bladder cancer
A biomarker signal in bladder cancer patients treated with anti-PD-L1 therapies — amplification of the target gene was associated with worse outcomes. The findings shaped the biotech's view of an underserved patient population.
Case study available on request
Get started

Replace chance with evidence.

30 minutes. Bring your program. We'll walk through what's already running in your indication, and what Lens can do for you.

Book a demo
Book a demo →